U.S. markets close in 6 hours 15 minutes
  • S&P 500

    4,217.55
    +15.93 (+0.38%)
     
  • Dow 30

    34,630.08
    +81.55 (+0.24%)
     
  • Nasdaq

    13,740.88
    +108.04 (+0.79%)
     
  • Russell 2000

    2,241.91
    +0.49 (+0.02%)
     
  • Crude Oil

    64.32
    -0.39 (-0.60%)
     
  • Gold

    1,827.60
    +11.90 (+0.66%)
     
  • Silver

    27.33
    -0.13 (-0.46%)
     
  • EUR/USD

    1.2109
    +0.0041 (+0.34%)
     
  • 10-Yr Bond

    1.5470
    -0.0140 (-0.90%)
     
  • GBP/USD

    1.3925
    +0.0033 (+0.24%)
     
  • USD/JPY

    108.8490
    -0.2360 (-0.22%)
     
  • BTC-USD

    57,387.62
    +58.62 (+0.10%)
     
  • CMC Crypto 200

    1,517.11
    +81.33 (+5.66%)
     
  • FTSE 100

    7,093.39
    +17.22 (+0.24%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Celyad Oncology Announces September 2020 Conference Schedule

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Regulatory News:

Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in September 2020:

Wells Fargo 2020 Virtual Healthcare Conference

Date: Wednesday, September 9, 2020
Time: 9:20 a.m. EDT
Webcast: A live and archived webcast of the fireside chat will be available in the Events section of the Celyad Oncology website

Knowledge for Growth 2020

Date: September 9 – September 10, 2020

H.C. Wainwright 22nd Annual Global Investment Conference

Date: Monday, September 14, 2020
Time: 3:30 p.m. EDT
Webcast: A live and archived webcast of the fireside chat will be available in the Events section of the Celyad Oncology website

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005909/en/

Contacts

Investors and Media:
Alexandrine Hazard
Communications & Investor Relations Associate
Celyad Oncology
investors@celyad.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com